Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-065940950f1dbb7c281e0e49d5dfc752"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-065940950f1dbb7c281e0e49d5dfc752"/>
<resource>
<Composition>
<id value="composition-en-065940950f1dbb7c281e0e49d5dfc752"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-065940950f1dbb7c281e0e49d5dfc752"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-065940950f1dbb7c281e0e49d5dfc752</b></p><a name="composition-en-065940950f1dbb7c281e0e49d5dfc752"> </a><a name="hccomposition-en-065940950f1dbb7c281e0e49d5dfc752"> </a><a name="composition-en-065940950f1dbb7c281e0e49d5dfc752-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/934/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - plegridy</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/934/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp065940950f1dbb7c281e0e49d5dfc752"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - plegridy"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><ol start="7" type="1"><li>Instructions for injecting Plegridy pre-filled syringe</li></ol></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Plegridy is and what it is used for</li><li>What you need to know before you use Plegridy</li><li>How to use Plegridy</li><li>Possible side effects</li><li>How to store Plegridy</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What plegridy is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What plegridy is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Plegridy is The active substance in Plegridy is peginterferon beta-1a. Peginterferon beta-1a is a modified long-acting form of interferon. Interferons are natural substances made in the body to help protect from infections and diseases.</p><p>What Plegridy is used for This medicine is used to treat relapsing-remitting multiple sclerosis (MS) in adults aged 18 or over.<br/>MS is a long term illness that affects the central nervous system (CNS), including the brain and spinal cord, in which the body s immune system (its natural defences) damages the protective layer (myelin) that surrounds the nerves in the brain and spinal cord. This disrupts the messages between the brain and other parts of the body, causing the symptoms of MS. Patients with relapsing-remitting MS have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).</p><p>Everyone has their own set of MS symptoms. These can include:</p><ul><li>Feeling off-balance or light headed, walking problems, stiffness and muscle spasms, tiredness, numbness in the face, arms or legs</li><li>Acute or chronic pain, bladder and bowel problems, sexual problems and problems with vision</li><li>Difficulty thinking and concentrating, depression.</li></ul><p>How Plegridy works Plegridy seems to work by stopping the body s immune system from damaging your brain and spinal cord. This can help to reduce the number of relapses that you have and slow down the disabling effects of MS. Treatment with Plegridy can help to prevent you from getting worse, although it will not cure MS.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take plegridy"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take plegridy"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Plegridy</p><ul><li>If you are allergic to peginterferon beta-1a, interferon beta-1a or any of the ingredients of this medicine (listed in section 6). See section 4 for the symptoms of an allergic reaction.</li><li>If you have severe depression or think about committing suicide.</li></ul><p>Warnings and precautions<br/>Talk to your doctor if you have ever had:</p><ul><li>Depression or problems affecting your mood</li><li>Thoughts about committing suicide</li><li>Your doctor may still prescribe Plegridy for you, but it s important to let your doctor know if you have had depression or any similar problems affecting your mood in the past.</li></ul><p>Talk to your doctor, pharmacist or nurse before injecting Plegridy if you have any of the conditions listed below. They may get worse while using Plegridy:</p><ul><li>Serious liver or kidney problems</li><li>Irritation at an injection site, which can lead to skin and tissue damage (injection site necrosis). When you are ready to inject, carefully follow the instructions in section 7 Instructions for injecting Plegridy pre-filled syringe , at the end of this leaflet. This is to reduce the risk of injection site reactions.</li><li>Epilepsy or other seizure disorders, not controlled by medicine</li><li>Heart problems, which can cause symptoms such as chest pain (angina), particularly after any activity; swollen ankles, shortness of breath (congestive heart failure); or an irregular heartbeat (arrhythmia).</li><li>Thyroid problems</li><li>A low number of white blood cells or platelets, which can cause an increased risk of infection, or bleeding</li></ul><p>Other things to consider when using Plegridy</p><ul><li>You will need blood tests to determine your numbers of blood cells, blood chemistry and your levels of liver enzymes. These will be performed before you start using Plegridy, regularly after treatment with Plegridy has been initiated and then periodically during treatment, even if you have no particular symptoms. These blood tests will be in addition to the tests which are normally done to monitor your MS.</li><li>The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor.</li><li>Blood clots in the small blood vessels may occur during your treatment. These blood clots could affect your kidneys. This might happen several weeks to several years after starting Plegridy. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidneys.</li></ul><p>If you accidentally prick yourself or someone else with the needle in Plegridy, the area affected should be washed immediately with soap and water and a doctor or nurse should be contacted as soon as possible.</p><p>Children and adolescents Plegridy is not to be used in children and adolescents below 18 years old. The safety and effectiveness of Plegridy in this age group are not known.</p><p>Other medicines and Plegridy Plegridy should be used carefully with medicines that are broken down in the body by a group of proteins called cytochrome P450 (e.g. some medicines used for epilepsy or depression).</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially those used to treat epilepsy or depression. This includes any medicines obtained without a prescription.</p><p>Sometimes you will need to remind other healthcare professionals that you are being treated with Plegridy. For example, if you are prescribed other medicines, or if you have a blood test. Plegridy may affect the other medicines or the test result.</p><p>Pregnancy and breast-feeding<br/>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br/>No harmful effects on the breastfed newborn/infant are anticipated. Plegridy can be used during breast- feeding.</p><p>Driving and using machines<br/>Plegridy has no or negligible influence on the ability to drive and use machines.</p><p>Plegridy contains sodium<br/>This medicine contains less than 1 mmol sodium (23 mg), that is to say it is essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take plegridy"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take plegridy"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The usual dose One injection of Plegridy 125 micrograms every 14 days (every two weeks). Try to use Plegridy at the same time on the same day, every time you inject.</p><p>Starting Plegridy If you are new to Plegridy, your doctor may advise you to gradually increase your dose so that you can adjust to the effects of Plegridy before taking the full dose. You will be provided with an Initiation Pack containing your first 2 injections: one orange syringe with Plegridy 63 micrograms (for day 0) and one blue syringe with Plegridy 94 micrograms (for day 14).</p><p>After that you will be provided with a maintenance pack containing grey syringes with Plegridy 125 micrograms (for day 28 and then every two weeks).</p><p>Read the instructions in section 7 Instructions for injecting Plegridy pre-filled syringe at the end of this leaflet before you start using Plegridy. Use the record table printed on the inside of the lid of the Initiation Pack to keep a track of your injection dates.</p><p>Injecting yourself Plegridy is to be injected under the skin (subcutaneous injection). Alternate the sites you use for injections. Do not use the same injection site for consecutive injections.</p><p>You can inject Plegridy yourself without the help of your doctor, if you have been trained how to do this.</p><ul><li>Read and follow the advice given in the instructions in section 7 Instructions for injecting Plegridy pre-filled syringe before you start.</li><li>If you have trouble handling the syringe, ask your doctor or nurse who may be able to help.</li></ul><p>How long to use Plegridy Your doctor will tell you how long you need to keep using Plegridy. It is important to continue using Plegridy regularly. Do not make changes unless your doctor tells you.</p><p>If you use more Plegridy than you should You must only inject Plegridy once every 2 weeks.</p><ul><li>If you have used more than one injection of Plegridy in a 7-day period, contact your doctor or nurse straight away.</li></ul><p>If you forget to use Plegridy You need to inject Plegridy once every 2 weeks. This regular schedule helps to deliver the treatment as evenly as possible.</p><p>If you do miss your usual day, inject as soon as you can and carry on as usual. However, do not inject more than once in a 7-day period. Do not use two injections to make up for a missed injection.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><ul><li><p>Liver problems (common - may affect up to 1 in 10 people) If you get any of these symptoms:</p></li><li><p>Yellowing of your skin or the whites of your eyes</p></li><li><p>Itching all over</p></li><li><p>Feeling sick, being sick (nausea and vomiting)</p></li><li><p>Easy bruising of the skin</p></li><li><p>Contact a doctor immediately. They may be signs of a possible liver problem.</p></li><li><p>Depression (common - may affect up to 1 in 10 people) If you:</p></li><li><p>Feel unusually sad, anxious or worthless or</p></li><li><p>Have thoughts about suicide</p></li><li><p>Contact a doctor immediately.</p></li><li><p>Serious allergic reaction (uncommon - may affect up to 1 in 100 people) If you get any of these:</p></li><li><p>Difficulty breathing</p></li><li><p>Swelling around the face (lips, tongue or throat)</p></li><li><p>Skin rashes or redness</p></li><li><p>Contact a doctor immediately.</p></li><li><p>Seizures (uncommon - may affect up to 1 in 100 people) If you have a seizure or a fit</p></li><li><p>Contact a doctor immediately.</p></li><li><p>Injection site damage (rare - may affect up to 1 in 1,000 people) If you get any of these symptoms:</p></li><li><p>Any break in the skin together with swelling, inflammation or fluid leaking around the injection site</p></li><li><p>Contact a doctor for advice.</p></li><li><p>Kidney problems including scarring that may reduce your kidney function<br/>(rare - may affect up to 1 in 1,000 people) If you get some or all of these symptoms:</p></li><li><p>Foamy urine</p></li><li><p>Fatigue</p></li><li><p>Swelling, particularly in the ankles and eyelids, and weight gain.</p></li><li><p>Contact a doctor as they may be signs of a possible kidney problem.</p></li><li><p>Blood problems<br/>(rare - may affect up to 1 in 1,000 people) The following may occur: Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness. Your doctor may find changes in your blood and the function of your kidneys.</p></li></ul><p>If you get some or all of these symptoms:</p><ul><li>Increased bruising or bleeding</li><li>Extreme weakness</li><li>Headache, dizziness or light-headedness</li><li>Contact a doctor immediately.</li></ul><p>Other side effects Very common side effects<br/>(may affect more than 1 in 10 people)</p><ul><li>Flu-like symptoms. These symptoms are not really flu, see below. You can t pass it on to anyone else.</li><li>Headache</li><li>Muscle pain (myalgia)</li><li>Pain in your joints, arms, legs or neck (arthralgia)</li><li>Chills</li><li>Fever</li><li>Feeling weak and tired (asthenia)</li><li>Redness, itching or pain around the place you have injected</li><li>If any of these effects trouble you, contact a doctor.</li></ul><p>Flu-like symptoms Flu-like symptoms are more common when you first start using Plegridy. They gradually get less as you keep using your injections. See below for simple ways to manage these flu-like symptoms if you get them.</p><p>Three simple ways to help reduce the impact of flu-like symptoms:</p><ol type="1"><li>Consider the timing of your Plegridy injection. The start and end of flu-like symptoms are different for every patient. On average, flu-like symptoms begin approximately 10 hours after injection and last between 12 and 24 hours.</li><li>Take paracetamol or ibuprofen half an hour before your Plegridy injection and continue to take paracetamol or ibuprofen for the duration of your flu-like symptoms. Speak to your doctor or pharmacist about how much to take and how long to take it.</li><li>If you have a fever, drink plenty of water to keep you hydrated.</li></ol><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>Feeling or being sick (nausea or vomiting)</li><li>Hair loss (alopecia)</li><li>Itchy skin (pruritus)</li><li>Increase in body temperature</li><li>Changes around the place you have injected such as swelling, inflammation, bruising, warmth, rash or colour change</li><li>Changes in your blood which might cause tiredness or reduced ability to fight infection</li><li>Increases in liver enzymes in the blood (will show up in blood tests)</li><li>If any of these effects trouble you, contact a doctor.</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li>Hives</li><li>Changes in your blood which might cause unexplained bruising or bleeding.</li><li>If any of these effects trouble you, contact a doctor.</li></ul><p>Frequency not known<br/>(frequency cannot be estimated from the available data)</p><ul><li>Pulmonary arterial hypertension: A disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with interferon beta-products.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.</p></div>
</text>
</section>
<section>
<title value="5. How to store plegridy"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store plegridy"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the label after EXP . The expiry date refers to the last day of that month.</p><ul><li><p>Store in the original package in order to protect from light. Only open the pack when you need a new syringe.</p></li><li><p>Store in a refrigerator (fridge) 2 -8 C.</p></li><li><p>Do not freeze. Throw away any Plegridy that is accidentally frozen.</p></li><li><p>Plegridy can be kept outside a fridge at room temperature (up to 25 C) for up to 30 days but it must be kept away from light.</p></li><li><p>Packs can be taken out of the fridge and then put back in a fridge more than once if you need to.</p></li><li><p>Make sure the time the syringes spend out of a fridge is no more than 30 days in total.</p></li><li><p>Throw away any syringe that is kept out of the fridge for more than 30 days.</p></li><li><p>If you are unsure of the number of days you have kept a syringe out of the fridge, throw the syringe away.</p></li><li><p>Do not use this medicine if you notice any of the following:</p></li><li><p>If the syringe is broken.</p></li><li><p>If the solution is coloured, cloudy or you can see particles floating in it.</p></li><li><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></li></ul></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Plegridy contains<br/>The active ingredient is peginterferon beta-1a.</p><p>Each 63 microgram pre-filled syringe contains 63 micrograms of peginterferon beta-1a in 0.5 mL solution for injection. Each 94 microgram pre-filled syringe contains 94 micrograms of peginterferon beta-1a in 0.5 mL solution for injection. Each 125 microgram pre-filled syringe contains 125 micrograms of peginterferon beta-1a in 0.5 mL solution for injection.</p><p>The other ingredients are: Sodium acetate trihydrate, acetic acid glacial, arginine hydrochloride, polysorbate 20 and water for injections (see Section 2 Plegridy contains sodium ).</p><p>What Plegridy looks like and contents of the pack Plegridy is a clear and colourless solution for injection in a glass pre-filled syringe with an attached needle.</p><p>Pack sizes:</p><ul><li>The Plegridy Initiation Pack contains one orange pre-filled syringe of 63 micrograms and one blue pre-filled syringe of 94 micrograms.</li><li>The 125 micrograms grey syringes are provided in a pack containing either two or six pre-filled syringes.</li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Biogen Netherlands B.V. Prins Mauritslaan 1171 LP Badhoevedorp The Netherlands</p><p>Manufacturer FUJIFILM Diosynth Biotechnologies Denmark ApS Biotek All 1 DK-3400 Hiller d Denmark</p><p>Biogen Netherlands B.V. Prins Mauritslaan 1171 LP Badhoevedorp The Netherlands</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Biogen Belgium NV/SA +32 2 2191Lietuva Biogen Lithuania UAB +370 5 259 6</p><p>+359 2 962 12 Luxembourg/Luxemburg Biogen Belgium NV/SA +32 2 2191 esk republika Biogen (Czech Republic) s.r.o. +420 255 706 Magyarorsz g Biogen Hungary Kft. +36 1 899 9Danmark Biogen Denmark A/S +45 77 41 57 Malta Pharma. MT Ltd.. +356 21337Deutschland Biogen GmbH +49 (0) 89 99 6Nederland Biogen Netherlands B.V. +31 20 542 2Eesti Biogen Estonia O<br/>+372 618 9Norge Biogen Norway AS +47 23 40 01<br/>Genesis Pharma SA +30 210 8771 sterreich Biogen Austria GmbH +43 1 484 46 Espa a Biogen Spain S.L. +34 91 310 7Polska Biogen Poland Sp. z o.o. +48 22 351 51 France Biogen France SAS +33 (0)1 41 37 9Portugal Biogen Portugal<br/>Sociedade Farmac utica, Unipessoal Lda. +351 21 318 8Hrvatska Biogen Pharma d.o.o. +385 1 775 73 Rom nia Johnson & Johnson Romania S.R.L.<br/>+40 21 207 18 Ireland Biogen Idec (Ireland) Ltd. +353 (0)1 463 7Slovenija Biogen Pharma d.o.o. +386 1 511 02 sland Icepharma hf +354 540 8Slovensk republika Biogen Slovakia s.r.o. +421 2 323 34Italia Biogen Italia s.r.l. +39 02 584 9Suomi/Finland Biogen Finland Oy +358 207 401<br/>Genesis Pharma Cyprus Ltd +357 22 76 57 Sverige Biogen Sweden AB +46 8 594 113 Latvija Biogen Latvia SIA +371 68 688 United Kingdom (Northern Ireland) Biogen Idec (Ireland) Limited +44 (0) 1628 50 1This leaflet was last revised in <{MM/YYYY}> <{month YYYY}>.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp065940950f1dbb7c281e0e49d5dfc752"/>
<resource>
<MedicinalProductDefinition>
<id value="mp065940950f1dbb7c281e0e49d5dfc752"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp065940950f1dbb7c281e0e49d5dfc752"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp065940950f1dbb7c281e0e49d5dfc752</b></p><a name="mp065940950f1dbb7c281e0e49d5dfc752"> </a><a name="hcmp065940950f1dbb7c281e0e49d5dfc752"> </a><a name="mp065940950f1dbb7c281e0e49d5dfc752-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/934/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Plegridy 63 micrograms solution for injection in pre-filled syringe</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/934/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Plegridy 63 micrograms solution for injection in pre-filled syringe"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
